Novel somatic mutations of the VHL gene in an erythropoietin-producing renal carcinoma associated with secondary polycythemia and elevated circulating endothelial progenitor cells

American Journal of Hematology

Volumn 83, Issue 2, 2008, Pages 155-158

  Rad, Farhad Haghighi ^a   Ulusakarya, Ayhan ^b   Gad, Sophie ^c   Sibony, Mathilde ^d   Juin, Fabrice ^a   Richard, Stéphane ^c   Machover, David ^b   Uzan, Georges ^a  

^a INSERM   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; DNA; ERYTHROPOIETIN; GROWTH FACTOR; LEUCINE; LYSINE; PROLINE;

AGED; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CARCINOGENESIS; CASE REPORT; CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; DNA EXTRACTION; ENDOTHELIUM; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MONONUCLEAR CELL; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION; STEM CELL; STEM CELL MOBILIZATION; TUMOR SUPPRESSOR GENE; VHL GENE;

AGED; CARCINOMA, RENAL CELL; DNA, NEOPLASM; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; HUMANS; KIDNEY NEOPLASMS; MALE; MUTATION; NEPHRECTOMY; POLYCYTHEMIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 38349141624     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21019     Document Type: Article

References (25)

1. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Gen 1994;7:85-90.
2. Richard S, Graff J, Lindau J, Resche F. Von Hippel-Lindau disease. Lancet 2004;363:1231-1234.
3. Ang SO, Chen H, Gordeuk VL, et al. Endemic polcythemia in Rusia: Mutation in the VHL gene. Blood Cells Mol Dis 2002;28:57-62.
4. Yang H, Kaelin WG. Molecular pathogenesis of the Von Hippel-Lindau hereditary cancer syndrome: Implications for oxygen sensing. Cell Growth Differ 2001;12:447-455.
5. Safran M, Kaelin WG. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003;111:779-783.
6. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
7. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
8. Rini B, Rixe O, Bukowski R, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer. J Clin Oncol 2005;23. Abstract 4509.
9. Escudier B, Szczylik C, Eisen T et al. Randomized phase III trial of Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. J Clin Oncol 2005;23. Abstract 4510.
10. Wiesener MS, Seyfarth M, Warnecke C, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002;99:3562-3565.
11. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:911-918.
12. Hardee ME, Kirkpatrick JP, Shan S, et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer 2005;93:1350-1355.
13. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
14. Hilbe W, Dirnhofer S, Oberwasserlechner F, et al. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 2004;57:965-969.
15. Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005;11:261-262.
16. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Eng J Med 2005;353:999-1007.
17. Rugo HS, Dickler MN, Scott JH, et al. Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation. J Clin Oncol 2005;23. Abstract 525.
18. Zbar B, Kishida T, Chen F, et al. Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe and Japan. Hum Mutat 1996;8:348-357.
19. Olschwang S, Richard S, Boisson C, et al. Germline mutations profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Hum Mutat 1998;12:424-430.
20. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-423.
21. Lee YS, Vortmeyer AO, Lubensky IA, et al. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal carcinoma. Clin Cancer Res 2005;11:1059-1064.
22. Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital disorder of oxygen sensing: Association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 2004;103:3924-3932.
23. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-1346.
24. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in diabetic proliferative retinopathy. N Engl J Med 2005;353:782-792.
25. Bompais H, Chagraoui J, Canron X, et al. Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. Blood 2004;103:2577-2584.